Achieving Normal Glucose In Hospital Settings

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to evaluate the efficacy and safety of 24 hours of closed-loop glucose control compared with standard diabetes treatment, in patients with type 2 diabetes treated by non-insulin glucose-lowering medications. This group is being studied as it is representative of patients with glucose dysregulation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cambridge
• Collaborator: Cambridge University Hospitals NHS Foundation Trust
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Aged 18 years or older

• Type 2 diabetes for at least 1 year as defined by WHO

• Treatment with glucose-lowering medication(s) (including Exenatide) for at least 6 mths

• HbA1c between 7.0% and 10.0% inclusive (measured within past 3 mths)

Exclusion Criteria:

• Autoimmune type 1 diabetes

• Type 2 diabetes treated with insulin

• Type 2 diabetes treated with diet control alone

• Known or suspected allergy against insulin

• Proliferative retinopathy

• Current or planned pregnancy or breast feeding

• Any physical or psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by the study clinician